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Diseases/conditions with diverse etiology, such as hemoglobinopathies, hereditary
hemochromatosis and menopause, could lead to chronic iron accumulation. This
condition is frequently associated with a bone phenotype; characterized by low
bone mass, osteoporosis/osteopenia, altered microarchitecture and biomechanics, and
increased incidence of fractures. Osteoporotic bone phenotype constitutes a major
complication in patients with iron overload. The purpose of this review is to summarize
what we have learnt about iron overload-associated bone loss from clinical studies
and animal models. Bone is a metabolically active tissue that undergoes continuous
remodeling with the involvement of osteoclasts that resorb mineralized bone, and
osteoblasts that form new bone. Growing evidence suggests that both increased bone
resorption and decreased bone formation are involved in the pathological bone-loss in
iron overload conditions. We will discuss the cellular and molecular mechanisms that are
involved in this detrimental process. Fuller understanding of this complex mechanism
may lead to the development of improved therapeutics meant to interrupt the pathologic
effects of excess iron on bone.
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INTRODUCTION
Nowadays, osteoporosis is a major public health problem, affecting millions of people worldwide,
and it is expected to further escalate due to the progressive aging of populations. Based on
demographic changes around the world and the incidence rates for hip fractures, it was estimated
that the number of hip fractures occurring in the world each year will exceed 6 million by 2050
(Cooper et al., 1992).
The first multivariate analysis showing that iron overload is an independent risk factor for
osteoporosis in patients with genetic hemochromatosis was published by Sinigaglia et al. (1997).
This observation was confirmed by further clinical studies revealing that bone weakening—
characterized by low bone mass, osteopenia, osteoporosis, altered microarchitecture and
biomechanics, as well as bone fractures—is one of the common features of iron overload conditions.
Moreover, a number of experimental models of iron overload have been established to confirm the
deleterious effect of iron on bone metabolism.
In adults the entire skeleton is replaced in about every 10 years in a process called
bone remodeling. Two major cell types are involved in bone remodeling: osteoclasts that
resorb bone tissue and osteoblasts that actively synthetize new bone to fill the resulting
lacunae. Osteoclasts differentiate from the monocyte/macrophage hematopoietic lineage, and
osteoblasts differentiate from multipotent mesenchymal stem cells. Differentiation and activity
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of osteoclasts and osteoblasts must be tightly regulated in order
to maintain skeletal health throughout life. There is growing
evidence that excess iron disturb the delicate balance in bone
remodeling.
DETRIMENTAL ROLE OF EXCESS IRON
ON BONE DENSITY,
MICROARCHITECTURE, AND
BIOMECHANICS
Diseases/conditions with diverse etiology, such as
hemoglobinopathies, hereditary hemochromatosis and
menopause, could lead to chronic iron accumulation. Case
reports and clinical studies revealed that bone weakening—
characterized by low bone mass, osteopenia, osteoporosis,
altered microarchitecture and biomechanics, as well as bone
fractures—is one of the common features of these iron overload
conditions. Moreover, osteoporotic bone phenotype has been
observed in diverse animal models of iron overload, suggesting a
detrimental role of excess iron on bone.
Clinical Findings
Thalassemia Bone Disease
Thalassemias are inherited blood disorders due to diverse
mutations in the genes encoding hemoglobin (Hb) chains
(α and β) causing various degrees of anemia (Weatherall,
1997). Severity of thalassemia varies widely from mild anemia
(thalassemia intermedia) through severe forms (thalassemia
major) to intrauterine death. Thalassemia major patients are on
regular blood transfusion therapy in order to maintain sufficient
Hb levels (Weatherall, 1997). The human body lacks active
mechanism to excrete excess iron, therefore repeated blood
transfusions lead to iron overload in these patients. Excess iron
can deposit in body organs in particularly in pancreas, liver,
pituitary, and the heart. To avoid iron overload, thalassemia
patients are treated with iron chelators concomitantly with the
blood transfusions (Bayanzay and Alzoebie, 2016). In spite of
iron chelation therapy, iron overload is a major manifestation
of the disease that contributes largely to the multiple end-organ
complications associated with thalassemia major.
Thalassemia-associated osteoporosis and subsequent bone
fractures remained to be one of the most frequent co-morbidity
in thalassemia patients (reviewed in Dede et al., 2016). According
to the findings of clinical studies performed in the last 40 years,
fracture rates decreased in thalassemia patients, that could be due
to the improvement of iron chelation therapy (Dines et al., 1976;
Exarchou et al., 1984; Finsterbush et al., 1985; Ruggiero and De
Sanctis, 1998; Fung et al., 2008). A recent cohort published in
2006 reported increased prevalence of lifetime fracture rate in
both thalassemia major and thalassemia intermedia patients, that
could be associated with increased life expectancy of the patients
and older age of the population group (Vogiatzi et al., 2006).
Importantly, fracture risk correlates with severity of anemia and
the frequency of blood transfusion in patients with thalassemia.
Bone mineral density (BMD) is a good predictor of fractures
in thalassemia patients similarly to that of healthy subjects.
Prevalence of low BMD is increasing sharply by age in
thalassemia patients. For example decreased BMD is present
in less than 10% of children with thalassemia (6–10 years) but
more than 60% of the adult patients (>20 years) have low BMD,
regardless of optimal treatment (Vogiatzi et al., 2006). Because
low BMD alone cannot explain the high fracture risk described
in patients with thalassemia, further studies were performed
to study bone quality. Trabecular bone score, as a measure of
bone quality, was found to be lower in adults with thalassemia
compared to healthy individuals (Baldini et al., 2014). Similarly
to that of BMD, trabecular bone score also correlated with
age, suggesting that thalassemia negatively influence both bone
quality and quantity (Baldini et al., 2014).
Bone is a dynamic tissue, therefore diverse mechanisms could
contribute to low bone quantity and quality in thalassemia
patients. Several studies suggested the involvement of increased
bone resorption in the pathogenesis of thalassemia-associated
bone disease (Voskaridou et al., 2001; Morabito et al., 2004;
Vogiatzi et al., 2006; Angelopoulos et al., 2007). Other studies
proposed that bone formation is severely impaired in patients
with thalassemia. Bone histomorphometry revealed that osteoid
thickness and osteoid maturation time are increased in iliac crest
of children with β-thalassemia indicating impaired bone matrix
maturation and defective mineralization (Mahachoklertwattana
et al., 2003). Interestingly, iron deposits were detected along
mineralization fronts and osteoid surfaces, and were co-
localized with thickened osteoid seams (Bordat et al., 1993;
Mahachoklertwattana et al., 2003).
Sickle Cell Bone Disease
Sickle cell disease (SCD) is an inherited autosomal recessive
disorder, caused by a single nucleotide mutation in the Hb β-
chain coding gene (HBB). SCD is one of the most prevalent
genetic blood disorders worldwide affecting more than 300,000
annual births. SCD is associated with significant morbidity and
shortened life span (45–65 years; Hamideh and Alvarez, 2013).
Bone involvement is very common in SCD and can manifest
in diverse ways including but not limited to bone and joint
pain, vertebral bone deformities, osteopenia and osteoporosis
and pathological fractures (reviewed in Almeida and Roberts,
2005; Osunkwo, 2013). Low BMD in present in more than 70% of
SCD patients at the age of 30 years that predispose those patients
to high risk of fractures and vertebral collapse (Miller et al., 2006;
Sadat-Ali and Al Elq, 2007; Sarrai et al., 2007; Sadat-Ali et al.,
2008). Although the association between SCD and low BMD is
well established, there are very few studies addressing the reason
of low BMD in SCD. Recently, Baldanzi et al. (2011) analyzed
65 SCD patients and found that low BMD was associated with
increased hemolysis, which was characterized by increased lactate
dehydrogenase levels and reticulocyte counts as well as decreased
hemoglobin levels.
Iron status of SCD patients is quite controversial, as some
reports suggest that SCD is associated with iron overload while
others describe SCD as a condition of iron deficiency (Koduri,
2003; Koren et al., 2010). This might be due to the abnormal
compartmentalization of iron in SCD patients that can lead to
hepatic, splenic, and renal siderosis but no iron stores in the bone
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marrow, simultaneously (Natta et al., 1985). Moreover, autopsy
studies revealed huge individual variations in iron deposits in
SCD patients (Natta et al., 1985). Nevertheless, a recent cross-
sectional study revealed that about 70% of SCD patients with high
serum iron had lower bonemass, thus suggesting a negative effect
of excess iron—if present in SCD—on bone physiology (Sadat-Ali
et al., 2011).
Bone Abnormalities in Hereditary Hemochromatosis
Hemochromatosis refers to a group of inherited disorders
characterized by increased dietary iron uptake, which in some
cases can lead to severe tissue iron overload. Up to date five
types of hereditary hemochromatosis are described, each caused
by mutations in different genes involved in iron metabolism.
The most common form of hereditary hemochromatosis
(HH) in Caucasian population is due to the Cys282Tyr
mutation of the HFE gene (Feder et al., 1996; McLaren and
Gordeuk, 2009). Other types of hereditary hemochromatosis
are caused by mutations in the transferrin receptor-2 gene
(TfR2) (Camaschella et al., 2000), hemojuvelin gene (HJV)
(Papanikolaou et al., 2004), hepcidin gene (HAMP) (Roetto
et al., 2003), and the ferroportin gene (SCL40A1) (Pietrangelo,
2004).
In the last 50 years evidence piled up suggesting the
adverse effect of HH on joints and bones (reviewed in
Guggenbuhl et al., 2011a). Case reports and small-scale studies
suggested that HH is associated with osteoporosis, and that
the development of osteoporosis correlates with the severity
of iron overload independently of cirrhosis and hypogonadism
(Diamond et al., 1989; Sinigaglia et al., 1997; Guggenbuhl et al.,
2005; Angelopoulos et al., 2006). Recently, the incidences of
osteoporosis and osteopenia were determined in patients with
HH. These studies revealed that about 25–34% of HH patients
have osteoporosis and 40–80% of the patients have osteopenia
(Guggenbuhl et al., 2005; Valenti et al., 2009). A recent case-
control study with the involvement of ∼300 HH patients and
∼300 age-, and sex-matched controls clearly showed that HH
is associated with increased prevalence of osteoporosis (Richette
et al., 2010). Osteoporotic fractures were described in some HH
patients (Eyres et al., 1992; Duquenne et al., 1996), and the
above-mentioned study showed that patients with HH showed
an increased prevalence, although not significant, of wrist and
vertebral fractures. Moreover the same study revealed that the
severity of iron overload was associated with wrist and vertebral
fractures.
Postmenopausal Osteoporosis
Postmenopausal osteoporosis is a systemic bone metabolism
disorder affecting 30% of women over the age of 50 (reviewed
recently in Black and Rosen, 2016). The disease is characterized
by progressive bone loss and subsequent increase in the risk
of fractures. Among postmenopausal white women the lifetime
risk of hip fracture is 15–20%, and the risk of any osteoporotic
fractures is about 50% (Cummings et al., 1989; Cummings and
Melton, 2002).
Estrogen deficiency, a prominent feature of menopause, has
been considered as the main cause of menopausal symptoms
and disorders. For example, estrogen deficiency has been shown
to change bone metabolism via promoting bone resorption
and decreasing bone formation, and therefore contribute to
postmenopausal osteoporosis (Bowring and Francis, 2011).
Menopausal transition is a complex process, in which besides
hormonal shifts, iron metabolism is also altered. Parallel with
the decline in estrogen level, a two- to three-fold increase in
serum ferritin concentration was detected in postmenopausal
women (Milman and Kirchhoff, 1992; Zacharski et al., 2000).
Although elevated iron as a result of menopause is in the
physiologic range, mounting evidence suggest that besides
estrogen deficiency, iron/ferritin accumulation affect the health
of postmenopausal women (Jian et al., 2009). Recent studies
investigated the association between plasma ferritin level and
BMD. Kim et al. (2012) performed a 3-year retrospective
longitudinal study with the involvement of 940 postmenopausal
women in which they determined annual bone loss rates and
plasma ferritin levels. They found that rates of bone loss were
significantly accelerated in a dose-dependent manner across
increasing ferritin quartile categories. Results of a population-
based, cross-sectional study from the Korea National Health
and Nutrition Examination Surveys provided further evidence
that there is an inverse correlation between serum ferritin
level and BMD in women ≥45 years of age (Kim et al.,
2013). These studies provided clinical evidence that increased
total body iron stores could be an independent risk factor for
accelerated bone loss in postmenopausal women. Interestingly,
bisphosphonates, a widely used agent to treat osteoporosis in
postmenopausal women has been shown to decrease plasma
ferritin levels significantly (Feldbrin et al., 2016). Whether this
effect of bisphosphonates, contributes to its anti-osteoporosis
action, needs to be investigated in the future.
Animal Models
As it was discussed in the previous chapter, iron overload
associates with osteoporosis and bone fractures, but it remained
elucidated whether this is due to a direct effect of iron on
bone metabolism, or is the result of simultaneous endocrine
alterations, or the effect of chronic illness itself. To answer this
question Tsay et al. (2010) developed a mouse model of iron
overload in which C57/BL6 mice were injected with iron dextran
for 2 months. This approach resulted in tissue iron overload
in various organs, including liver, spleen, and heart which was
associated with osteoporosis (Tsay et al., 2010). Iron overload-
driven bone loss was associated with increased production of
reactive oxygen species (ROS) and inflammatory cytokines such
as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)
(Tsay et al., 2010). The free radical scavenger N-acetyl-L-cysteine
(NAC) could partially prevent the development of iron overload-
triggered bone abnormalities, highlighting the critical role of ROS
in the mechanism of bone loss (Tsay et al., 2010).
Bone phenotype was studied in several genetic iron overload
mouse models as well. For example both heterozygous and
homozygous th3 thalassemia mice as well as hemizygous
β-globin knockout and βIVSII−654 knockin thalassemic mice
exhibited decreased trabecular bone fraction and thickness, lower
number of trabeculae, thinner cortices and increased marrow
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area (Vogiatzi et al., 2010; Thongchote et al., 2014, 2015).
These changes in bone microarchitecture were associated with
decreased bone turnover and poor biomechanical properties in
the thalassemia mice models (Vogiatzi et al., 2010; Thongchote
et al., 2014). Regarding sickle cell disease, deleterious structural
changes in the bone microarchitecture and mechanics as well
as decreased BMD were detected in aged transgenic sickle cell
disease and sickle cell trait mice (Green et al., 2015; Xiao et al.,
2016).
Studies accomplished using genetic mice models of
hemochromatosis also supported the negative influence of
excess iron on bone metabolism. For example Hfe knockout
(Hfe−/−) mice had a phenotype of osteoporosis with low bone
mass and alteration of the bone microarchitecture (Guggenbuhl
et al., 2011b; Doyard et al., 2016). Similar bone phenotype was
described in hepcidin deficient (Hamp1−/−) mice (Shen et al.,
2014; Sun et al., 2014) and in zebrafish (Jiang et al., 2016). The
mechanism and the pathophysiological role of iron accumulation
in postmenopausal osteoporosis were also investigated using
animal models. In a recent study Xiao et al. (2015) found that
iron overload aggravated ovariectomy-induced bone-loss in
mice. Studies revealed that iron-induced oxidative stress could
contribute to deterioration of bone metabolism and subsequent
osteoporosis after menopause (Isomura et al., 2004; Xiao et al.,
2015).
Bone remodeling, the cycle of bone resorption and bone
formation, is critically important to maintain skeletal health
throughout life. In bone remodeling osteoclasts resorb bone
tissue and osteoblasts actively synthetize new bone tissue.
Growing evidence suggest that excess iron disturb the delicate
balance between bone resorption and bone formation which can
manifest as low bone mass, osteopenia, osteoporosis, or bone
fractures. Studies revealed that excess iron can influence both
osteoclast and osteoblast functions.
CELLULAR MECHANISMS
Bone is a metabolically active tissue that undergoes continuous
remodeling with the involvement of osteoclasts that resorb
mineralized bone, and osteoblasts that form new bone matrix
(Zaidi, 2007). In vivo observations revealed that both increased
bone resorption and decreased bone formation are involved
in the pathological bone-loss in iron overload conditions
(Figure 1). Osteoclasts derive from the monocyte/macrophage
hematopoietic lineage, and osteoblasts differentiate from
multipotent mesenchymal stem cells. The in vitro effect of
excess iron on osteoclast and osteoblast functions and their
differentiation processes have been studied and will be discussed
in this chapter.
The Effects of Iron Overload in Bone
Resorption
Influence of Iron on Osteoclast Differentiation and
Activity: In vitro Findings
Osteoclasts are differentiated from myeloid cells of the
monocyte/macrophage lineage. The differentiation is initiated by
osteoclastogenic cytokines, i.e., macrophage colony-stimulating
factor (M-CSF) and receptor activator of nuclear factor κB
ligand (RANKL) (Teitelbaum and Ross, 2003). RANKL is
controlled by osteoprotegerin (OPG), a decoy receptor for
RANKL, which inhibits osteoclastogenesis. Therefore, the
RANKL/OPG pathway is the dominant regulator of osteoclast
proliferation and activation (Hofbauer et al., 2004), and the
RANKL/OPG ratio is an important determinant of bone mass
and skeletal integrity (Boyce and Xing, 2007). Following the
formation of mononuclear pre-osteoclasts, they fuse and form
the multinuclear mature osteoclasts which die of apoptosis
within a few days. Osteoclasts are effector cells that are involved
in breaking down bone tissue. They seal the resorption bays,
and form a specialized cell membrane, the ruﬄed border at the
site of active bone resorption. Osteoclast release hydrogen ions
into the resorption cavity, to acidify the milieu, that facilitates
the dissolution of the inorganic bone matrix (Teitelbaum and
Ross, 2003; Ikeda and Takeshita, 2016). Additionally, activated
osteoclasts secrete proteolytic enzymes, such as cathepsins
and matrix metalloproteinases, which degrade bone matrix
proteins (Teitelbaum and Ross, 2003; Ikeda and Takeshita,
2016). Mature osteoclasts highly express tartrate-resistant
acid phosphatase (TRAP) that they release upon active bone
resorption. Consequently, TRAP 5b is a useful serum marker of
bone resorption (Halleen et al., 2000).
Accumulating evidence suggest that iron facilitate osteoclast
differentiation, activation and bone resorption (Figure 1).
Osteoclasts have high energy demand which is fueled by a lot of
mitochondria (Roodman, 2009). Mitochondrial biogenesis is an
iron-dependent process, because the proteins of the respiratory
chain are iron-containing proteins. Osteoclast differentiation
was found to be associated with the induction of transferrin
receptor 1 (Tfr1) and increased iron uptake (Ishii et al.,
2009; Roodman, 2009). Tfr1-mediated iron uptake facilitated
osteoclast differentiation and bone-resorbing activity, whereas
iron chelation inhibited osteoclastic bone resorption (Ishii et al.,
2009). This finding was confirmed by Jia et al. (2012) who
showed that ferric ion promoted RANKL-induced osteoclast
formation in both RAW264.7 cells and bone marrow-derived
macrophages. Iron catalyzes the formation of ROS and this
effect was found to be critical in iron-mediated promotion
of osteoclast differentiation (Jia et al., 2012). Iron chelation
approaches provided further evidence to establish the central role
of iron in osteoclastogenesis. Cornish et al. (2004) found that
lactoferrin, an iron-binding glycoprotein, at a concentration of
100µg/ml, completely arrested osteoclastogenic differentiation
of monocytes, which was associated with decreased expression
of RANKL. Iron overload conditions are associated with
elevated RANKL/OPG ratio (Morabito et al., 2004), whereas
the iron-chelating lactoferrin has been shown to improve bone
density via decreasing RANKL/OPG ratio (Hou et al., 2012).
Besides affecting osteoclastogenesis, growing evidence
suggest that iron influences mature osteoclast activity and
bone resorption as well. Early studies showed that inhibition
of TRAP activity in osteoclasts abolishes bone resorption
(Zaidi et al., 1989). TRAP contains 2 iron atoms/molecule,
and its activity is rapidly inhibited by a ferric chelator but not
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FIGURE 1 | Cellular mechanisms involved in iron overload-associated bone-loss. Osteoclasts are differentiated from myeloid cells of the
monocyte/macrophage lineage. The differentiation is initiated by macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand
(RANKL). Multinuclear osteoclasts are formed via the fusion of mononuclear osteoclast precursors. Iron facilitates osteoclast differentiation, activation and bone
resorption. Osteoblasts derive from multipotent mesenchymal stem cells (MSCs). Iron inhibits osteogenic differentiation of MSCs via the downregulation of the master
osteogenic transcription factor runt-related transcription factor 2 (Runx2). Iron impairs Runx2-dependent upregulation of osteoblast-specific proteins, e.g., alkaline
phosphatase (ALP) and osteocalcin (OCN), and inhibits extracellular matrix mineralization. Increased bone destruction by osteoclasts and decreased bone formation
by osteoblasts contribute to bone loss in patients with systemic iron-overload.
by a ferrous chelator, suggesting that ferric iron is essential
for enzymatic catalysis (Hayman et al., 1989; Hayman and
Cox, 1994). Additionally, Alcantara et al. (1994) showed
that TRAP mRNA contains an iron regulatory element
at the 5′-flanking sequence, therefore TRAP expression
is regulated by iron at the level of gene transcription.
Overall, these studies revealed that iron excess can facilitate
bone resorption by facilitating osteoclastogenesis and by
increasing osteoclast activity. These mechanisms could
contribute to unbalanced bone remodeling in iron-overload
diseases.
Influence of Iron Overload on Bone Resorption:
In vivo Findings
Iron overload-associated bone weakening was shown by several
experimental animal models. In some of these works the
authors tried to dissect whether the observed bone phenotype
is associated with increased bone resorption or decreased bone
formation (Table 1). Based on bone histomorphometry, Tsay
et al. (2010) revealed that the osteoporotic phenotype of iron
overloaded C57/BL6 mice is associated with increased number
of osteoclasts in the bone tissue. Moreover, the study of
Guggenbuhl et al. (2011b) on Hfe−/− mice led to the same
conclusion that iron-overload mediated bone loss is due to
elevated numbers of osteoclasts. Furthermore, Sun et al. (2014)
found that the level of C-telopeptide of type-I collagen, a
serum bone resorption marker, is elevated in Hamp−/− mice,
suggesting that increased osteoclast activity contributes to bone-
loss in those mice. These studies suggested that increased
bone resorption rather than decreased bone formation is the
underlying mechanism of iron overload-associated bone loss
(Table 1).
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TABLE 1 | Studies addressing the effects of iron overload in bone remodeling.
Experimental model Major findings Experimental approach References
C57BL/6 mice iron dextran treatment Increased osteoclast number Bone histomorphometry Tsay et al., 2010
Hfe−/− mice Increased osteoclast number Bone histomorphometry Guggenbuhl et al., 2011b
Hamp1−/− mice Increased osteoclast activity ELISA; serum C-telopeptide of type I collagen Sun et al., 2014
th3/th3 thalassemia mice Decreased bone formation and
decreased bone resorption
Bone histomorphometry Vogiatzi et al., 2010
β-globin knock-out thalassemic mice Decreased bone formation and
increased bone resorption
Bone histomorphometry Thongchote et al., 2015
Townes transgenic sickle mice Decreased terminal differentiation of
osteoblasts
qRT-PCR; ALP, OCN, Runx2, osterix mRNA Xiao et al., 2016
Hfe−/− mice Decreased bone formation Reduced
number of active osteoblasts
Bone histomorphometry, histology Doyard et al., 2016
Hamp1−/− mice Decreased osteoblast activity ELISA; serum OCN Shen et al., 2014
Hamp1 knockdown zebrafish Decreased osteoblast activity qRT-PCR; Runx2a, Runx2b, osterix mRNA Jiang et al., 2016
Postmenopausal Wistar rats Decreased bone formation ELISA; serum OCN, serum ALP activity Isomura et al., 2004
C57BL/6 mice iron dextran treatment Decreased osteogenic differentiation
of osteoprogenitors
qRT-PCR; Runx2 mRNA Balogh et al., 2016
Hfe−/− hemochromatosis protein deficient, Hamp−/− hepcidin deficient, ELISA enzyme-linked immunosorbent assay, qRT-PCR quantitative real time PCR, ALP alkaline phosphatase,
OCN osteocalcin, Runx2 Runt-related factor 2.
The Effects of Iron Overload in Bone
Formation
Influence of Iron on Osteoblast Differentiation and
Activity: In vitro Findings
Osteoblasts derive from multipotent mesenchymal stem cells
(MSCs), which migrate to the site of injury, proliferate and
differentiate. Osteogenic potential of these bone marrow-derived
MSCs (BMSCs) is of crucial importance for proper remodeling
and/or healing, which is highlighted by the recent discovery,
that osteoporosis is associated with increased number, but
low osteogenic potential of circulating MSCs (Dalle Carbonare
et al., 2009). Many secreted differentiation factors, including
transforming growth factor-beta 1, fibroblast growth factor, bone
morphogenetic protein, wingless proteins, Indian HedgeHog can
activate those signaling mechanisms that involved in osteogenic
differentiation of MSCs (Hayrapetyan et al., 2015). These diverse
pathways all converge on the master osteogenic transcription
factor, runt-related transcription factor 2 (Runx2) (Franceschi
et al., 2003). The absence of Runx2 in mice results impaired bone
formation, the lack of differentiated osteoblasts, and eventually
leads to death shortly after birth (Komori et al., 1997; Otto
et al., 1997). Transcription of the major bone-specific proteins,
such as osteocalcin (OCN), osteopontin, bone sialoprotein (BSP),
α1 type I collagen (Col I) and alkaline phosphatase (ALP) are
under the control of Runx2 (Ducy et al., 1997). Recently, the
critical involvement of ROS in osteogenesis was established,
as a common denominator of the diverse osteogenic signaling
pathways (Atashi et al., 2015). Studies revealed that tightly
regulated levels of ROS are critical in osteogenic differentiation
of MSCs (Atashi et al., 2015).
Recently, Balogh et al. (2016) showed that iron selectively
inhibits osteogenic differentiation of BMSCs without influencing
adipogenic and chondrogenic differentiation. Iron at the
concentration of 50 µmol/L completely abolished osteogenic
stimuli-induced upregulation of Runx2 and its target genes OCN
and ALP (Balogh et al., 2016). The anti-osteogenic effect of
iron was mimicked by exogenously administered ferritin, the
major intracellular iron storage protein (Balogh et al., 2016).
Some other studies, originated from the field of stem cell-
based therapeutics, also supported the inhibitory nature of iron
on osteogenic differentiation of MSCs. For example it was
reported that superparamagnetic iron oxide nanoparticles—that
are widely used for labeling and in vivo tracking of MSCs—
increased intracellular iron content in MSCs and impaired
osteogenic differentiation of human MSCs (Chen et al., 2010;
Chang et al., 2012). Moreover, the iron chelator desferrioxamine
(DFO) abolished the anti-osteogenic effect of superparamagnetic
iron oxide nanoparticles, demonstrating the crucial role of
free iron in the inhibition of osteogenic differentiation of
MSCs (Chen et al., 2010). Recently, the involvement of Wnt/β-
catenin pathway—a critical regulator of bone remodeling—
was examined in iron-modulated osteogenic differentiation of
osteoblast progenitors. Qu et al. (2008) showed that DFO
increases ALP activity and calcium deposition of MSCs which
was accompanied by promoted phosphorylation of glycogen
synthase kinase-3β (GSK-3β) and increased β-catenin levels.
Baschant et al. (2016) showed that DFO induced the expression
of Wnt5a and identified Wnt5a as a key target for the pro-
osteogenic effect of DFO. Messer et al. (2009) investigated how
excess iron influence differentiation and function of fetal rat
calvaria cells. They showed that osteoblast phenotypic gene
markers were downregulated, and the capacity of iron-loaded
cells to form mineralized bone nodules was decreased. This work
suggested that not only osteogenic differentiation, but activity
and extracellular matrix mineralization of mature osteoblasts are
also negatively influenced by excess iron.
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The question whether excess iron affect osteoblast function
arose more than 25 years ago, and initial studies showed
that iron at high concentration diminish cellular proliferation
and function of osteoblast-like osteosarcoma cells (Diamond
et al., 1991). Then Messer et al. (2009) showed that excess
iron (0–10 µmol/L) results in rapid and sustained down-
regulation of transferrin receptor and a later up-regulation of
light and heavy chain ferritins in osteoblasts obtained from
fetal rat calvaria. Concurrently with these changes, osteoblast
phenotype gene markers, ALP, OCN, BSP, and Col I were
suppressed by day 15, and a decreased number of mineralized
nodules at day 20 were observed (Messer et al., 2009).
They also observed apoptotic events within 24 h of iron
loading (Messer et al., 2009). Zarjou et al. (2010) showed
that iron (0–50 µmol/L) dose-dependently downregulated the
expression of Runx2 and its target genes OCN and ALP in
mature human osteoblasts. This effect of iron was accompanied
by diminished mineralization of the extracellular matrix of
osteoblasts. That study also demonstrated that iron-mediated
suppressions of osteoblast activity and extracellular matrix
mineralization are provided by iron-induced upregulation of
ferritin, and its ferroxidase activity (Zarjou et al., 2009, 2010).
This observation was supported by further investigations in
which the authors showed that iron/ferritin inhibits osteoblast
activity and extracellular matrix mineralization induced by bone
morphogenetic protein 2 or β-glycerophosphate and activated
vitamin D3 (Yang et al., 2011; Becs et al., 2016). Studying the
underlying signaling mechanism of iron-mediated inhibition of
osteoblast activity revealed that excess iron decreased mRNA
level of HedgeHog Interacting Protein Like-2 gene, encoding
an inhibitor of the HedgeHog signaling pathway (Doyard et al.,
2012).
Influence of Iron Overload on Bone Formation: In vivo
Findings
In the last decade several in vivo animal studies revealed
that iron overload influence bone formation (Table 1).
Bone histomorphometry showed decreased bone formation
in both th3 thalassemia mice and hemizygous β-globin
knockout mice (Vogiatzi et al., 2010; Thongchote et al., 2015).
Doyard et al. (2016) also showed reduced number of active
osteoblasts in Hfe−/− mice. Xiao et al. (2016) found low
mRNA expressions of osteoblast markers including ALP,
Runx2, osterix, and OCN in tibia of Townes transgenic
sickle mice, and concluded that iron overload reduced
terminal differentiation of osteoblasts in these mice, Shen
et al. reported decreased OCN serum levels in hepcidin
deficient mice, whereas Jiang et al. (2016) showed decreased
Runx2a, Runx2b, and osterix mRNA levels in hepcidin
knockdown zebrafish. These studies suggested that osteoporotic
phenotype associated with hepcidin deficiency, is due to
decreased osteoblast activity and delayed mineralization.
Recently, Balogh et al. (2016) showed that iron overload
in C57BL/6 mice, is associated with decreased osteogenic
commitment and differentiation potential of compact-bone
resident osteoprogenitor cells, characterized by decreased Runx2
mRNA level.
EFFECT OF CHELATION THERAPY ON
IRON OVERLOAD-ASSOCIATED BONE
DISEASE
Iron chelation therapy is the main treatment of patients with
systemic iron overload (Fabio et al., 2007; Kalpatthi et al.,
2010; Maggio et al., 2011). Currently three main iron chelators
are used in the clinical practice, i.e., DFO, deferiprone, and
deferasirox (Maggio, 2007). Effectiveness of these iron chelators
were extensively studied with the use of different outcomes,
including ejection fraction, liver iron content, myocardial
iron concentration, serum ferritin, and urinary iron excretion
(reviewed in Maggio et al., 2011). Although the pathogenesis
of bone disease in iron-overload patients is multifactorial, the
direct detrimental effects of excess iron in bone physiology
and remodeling are well established. Therefore, iron chelation
therapy might be implicated in the prevention or management
of iron-overload-associated bone disease, although the number of
studies that specifically addressed this question remained limited.
A small study of Christoforidis et al. (2007) with the involvement
of 35 thalassemia patients revealed that optimal chelation therapy
prevented the manifestation of osteopenia/osteoporosis in the
first two decades of life. Casale et al. (2014) investigated the
effect of long term deferasirox therapy on bone disease in
adult β-thalassemia major patients. In that retrospective cohort
study, 86 transfusion-dependent thalassemia major patients were
involved, who were treated with deferasirox once daily, for a
median duration of 6.5 years (Casale et al., 2014). They found
that BMD of the lumbar spine increased, and the number
of patients with lumbar spine osteoporosis decreased, upon
chelation therapy. Importantly, the observed changes were
independent of bisphosphonate therapy, hormonal replacement
therapy, and calcium or vitamin D supplementation, suggesting
a direct positive effect of iron chelation on bone status in
those patients (Casale et al., 2014). In a recent study, Poggi
et al. (2016) compared the long-term effects of different iron
chelation regimens, in preventing bone disease in patients with β-
thalassemia major. In agreement with the previously mentioned
study (Casale et al., 2014), they observed a significant increase
in mean BMD T-score and a decrease in the prevalence of
osteoporosis in the patients receiving deferasirox (Poggi et al.,
2016). Surprisingly, the other iron chelation regimens (DFO
and deferiprone alone, or in combination) used in this study,
did not provide any beneficial effects on BMD (Poggi et al.,
2016). Although these investigations suggested that proper iron
chelation therapy prevents iron overload-associated bone disease,
a recent study performed by the Thalassemia Clinical Research
Network concluded that bone disease remained a frequent, and
unresolved problem in thalassemia (Vogiatzi et al., 2009).
CONCLUSIONS
Iron overload, can be of hereditary or acquired origin, is an
excess iron in the body that can accumulate in vital organs.
Iron overload increases the risk for liver disease, heart attack
or heart failure, and endocrine disorders. Additionally, this
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condition is frequently associated with a bone phenotype;
characterized by low bone mass, osteoporosis/osteopenia,
altered microarchitecture and biomechanics, and increased
incidence of fractures. Bone metabolism is a complex sequence
of bone resorption by osteoclasts, and bone formation by
osteoblasts. In order to maintain skeletal health, these processes
should be very well harmonized. Excess iron disturbs the
delicate balance between bone resorption and bone formation,
resulting in bone weakening. Evidence suggests that both
increased bone resorption, and decreased bone formation
are involved in the pathological bone-loss in iron overload
conditions.
Iron overload, if it remains untreated, can cause premature
death. Iron chelators are in the first line of therapeutic
interventions to prevent iron accumulation in vital organs.
With chelation therapy, the life expectancy of thalassemia
major patients is vastly improved, whereas early treatment
can confer normal life expectancy for patients with hereditary
hemochromatosis. As life expectancy of patients with iron-
overload increases, the prevalence of bone disease also increases,
suggesting that the current therapeutic interventions cannot
confer full protection for the bones. Further studies needed
to investigate the effects of iron chelation therapies on
bone metabolism. Fuller understanding of this complex
mechanism may lead to the improvement of current therapeutic
interventions meant to interrupt the pathologic effects of excess
iron on bone.
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